Enviomycin(EVM)による肺結核治療

概要

論文の詳細を見る
Nearly ten years have passed since the clinical use of Enviomycin (EVM) was initiated, however, further studies are required as to its therapeutic effects, side effects, etc. In order to elucidate the above points and to evaluate EVM through our experience, the clinical trial on EVM was carried out in ten hospitals and sanatoria for tuberculosis in Kanagawa prefecture. Patients previously untreated with or sensitive to VM and/or CPM were subjected to the study, and other anti-tuberculosis drugs were combined. EVM was used daily in principle for the initial 3 months, and in a few cases twice or three times a week. The results were summarized as follows: 1) Number of patients were 104, and patients more than 41 years old accounts for 80 percent, and the ratio of male to female was 2 to 1. 2) The majority of cases were launched EVM during treatment with other regimen or retreatment cases, however, 14 were original treatment cases. Cavitary patients occupied 81% of subjects. 3) The reasons of initiating EVM were to improve the effects, the presence of resistance to other antituberculous drugs and/or existence of hearing disturbance. 4) The EVM regimen was in principle 1g daily for the first three months, thereafter twice weekly for the next three months, however, several variations were observed, and in seven cases, EVM was injected daily for six months. 5) The therapeutic effects were difficult to evaluate, as the background of subjects was so diverse, however, one-half of case showed improvement in the general clinical conditions. As for improvement in X-ray findings and bacteriological findings by smear, one-thirds showed improvement, respectively. The proportion of cases showing improvement was higher in original treatment cases. 6) Local pain due to injection was slighter than the other antituberculous drugs such as SM, KM, VM, and CPM. 7) Incidence of side effects is comperatively low (4%), particularly cases showing loss of hearing was very few. In this connection, EVM may be worth while to try for patients suffering from hearing impairment due to high age.
一般社団法人日本結核病学会の論文

Enviomycin(EVM)による肺結核治療

スポンサーリンク

概要

著者

関連論文

スポンサーリンク